Provided by Tiger Trade Technology Pte. Ltd.

Repare Therapeutics Inc.

2.65
0.0000
Volume:- -
Turnover:3.22M
Market Cap:114.24M
PE:-1.56
High:2.65
Open:2.65
Low:2.65
Close:2.65
52wk High:2.66
52wk Low:0.8900
Shares:43.11M
Float Shares:22.72M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6944
EPS(LYR):-1.9969
ROE:-49.78%
ROA:-29.72%
PB:0.99
PE(LYR):-1.33

Loading ...

TD Cowen Downgrades Repare Therapeutics to Hold From Buy

MT Newswires Live
·
Nov 17, 2025

TD Cowen downgrades Repare Therapeutics (RPTX) to a Hold

TIPRANKS
·
Nov 17, 2025

Stocks to Watch: Taitron, Repare Therapeutics

Dow Jones
·
Nov 15, 2025

Repare Therapeutics to be Acquired by XenoTherapeutics in Strategic Move

TIPRANKS
·
Nov 15, 2025

Repare Therapeutics trading resumes

TIPRANKS
·
Nov 15, 2025

XenoTherapeutics to acquire Repare Therapeutics for $1.82 p/s plus one CVR

TIPRANKS
·
Nov 15, 2025

Repare Therapeutics Q3 EPS $0.08 Beats $(0.12) Estimate, Sales $11.620M Beat $7.500M Estimate

Benzinga
·
Nov 15, 2025

XenoTherapeutics to Acquire Repare Therapeutics for $1.82 Per Share Plus CVR

Reuters
·
Nov 15, 2025

Repare Therapeutics Inc - Shareholders Estimated to Receive $1.82 per Share

THOMSON REUTERS
·
Nov 15, 2025

Repare Therapeutics Enters Into Definitive Agreement to Be Acquired by Xenotherapeutics, Inc.

THOMSON REUTERS
·
Nov 15, 2025

Repare Therapeutics’ Promising Study on Advanced Solid Tumors: A Closer Look

TIPRANKS
·
Oct 28, 2025

Repare Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Oct 27, 2025

Repare Therapeutics Inc. : H.c. Wainwright Cuts Target Price to $3 From $5

THOMSON REUTERS
·
Oct 27, 2025

Repare Therapeutics Unveils Phase 1 LIONS Trial Data

TIPRANKS
·
Oct 23, 2025

Repare Therapeutics Unveils Preliminary Data from Phase 1 Trial of RP-1664 in Advanced Solid Tumors

Reuters
·
Oct 23, 2025

Repare Therapeutics Announces Initial Data from Phase 1 LIONS Trial of First-in-Class PLK4 Inhibitor RP-1664 in Advanced Solid Tumors

Reuters
·
Oct 14, 2025

Repare Therapeutics Q2 EPS $(0.39) Versus $(0.82) Prior Year, Sales $250.000K Versus $1.073M Prior Year

Benzinga
·
Aug 08, 2025

Repare Therapeutics Reports Q2 2025 Results: Revenues Drop to $0.3M, Net Loss Widens to $16.7M, EPS Falls to $0.39

Reuters
·
Aug 08, 2025

Repare Therapeutics Q2 Net Income USD -16.744 Million

THOMSON REUTERS
·
Aug 08, 2025

Repare Therapeutics Inc - Initial Data for Lions and Polar Trials Expected in Q4 2025

THOMSON REUTERS
·
Aug 08, 2025